Novel tool helps identify key targets to strengthen CAR NK cell therapies
Researchers developed the first genome-wide CRISPR screening tool for primary human natural killer (NK) cells
Study revealed critical regulators of NK cell activity that can be targeted to improve chimeric antigen receptor (CAR) NK cell therapies
Findings open new avenues for developing more effective CAR NK cell therapies for many cancers
HOUSTON, AUGUST 21, 2025 ― Natural killer (NK) cells became markedly better at killing cancer...
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three subgroups with...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.
Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall...
